InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: None

Monday, 10/18/2021 10:27:17 AM

Monday, October 18, 2021 10:27:17 AM

Post# of 44690
NRXP must drop claims to Zyesami, Relief’s therapeutic per the Doctrine of Equivalents

https://grr.com/publications/the-doctrine-of-equivalents-in-patents/

The bad news is that NRx is now facing a lawsuit from its partner, Relief Therapeutics (OTC:RLFT.F), alleging that NRx failed to honor its obligations under the duo's collaboration agreement.